JP7660066B2 - 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム - Google Patents
膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム Download PDFInfo
- Publication number
- JP7660066B2 JP7660066B2 JP2021551622A JP2021551622A JP7660066B2 JP 7660066 B2 JP7660066 B2 JP 7660066B2 JP 2021551622 A JP2021551622 A JP 2021551622A JP 2021551622 A JP2021551622 A JP 2021551622A JP 7660066 B2 JP7660066 B2 JP 7660066B2
- Authority
- JP
- Japan
- Prior art keywords
- bladder
- chondroitin sulfate
- distilled water
- added
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025059920A JP2025094276A (ja) | 2019-10-03 | 2025-03-31 | 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム、医薬組成物、及び膀胱疾患処置剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019183082 | 2019-10-03 | ||
| JP2019183082 | 2019-10-03 | ||
| PCT/JP2020/037640 WO2021066175A1 (ja) | 2019-10-03 | 2020-10-02 | 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025059920A Division JP2025094276A (ja) | 2019-10-03 | 2025-03-31 | 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム、医薬組成物、及び膀胱疾患処置剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021066175A1 JPWO2021066175A1 (cg-RX-API-DMAC7.html) | 2021-04-08 |
| JPWO2021066175A5 JPWO2021066175A5 (cg-RX-API-DMAC7.html) | 2023-10-02 |
| JP7660066B2 true JP7660066B2 (ja) | 2025-04-10 |
Family
ID=75338281
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021551622A Active JP7660066B2 (ja) | 2019-10-03 | 2020-10-02 | 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム |
| JP2025059920A Pending JP2025094276A (ja) | 2019-10-03 | 2025-03-31 | 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム、医薬組成物、及び膀胱疾患処置剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025059920A Pending JP2025094276A (ja) | 2019-10-03 | 2025-03-31 | 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム、医薬組成物、及び膀胱疾患処置剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220370630A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4039279A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7660066B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021066175A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023034903A1 (en) * | 2021-09-01 | 2023-03-09 | 3Helix, Inc. | Systems and methods for detecting fibrosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015005458A1 (ja) | 2013-07-10 | 2015-01-15 | 生化学工業株式会社 | グリコサミノグリカン誘導体及びその製造方法 |
| JP2017036455A (ja) | 2015-01-09 | 2017-02-16 | 生化学工業株式会社 | コンドロイチン硫酸誘導体及び膀胱疾患処置剤 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083933A (en) * | 1999-04-19 | 2000-07-04 | Stellar International Inc. | Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution |
| US20080306022A1 (en) | 2005-10-12 | 2008-12-11 | Kenji Miyamoto | Agent for Applying to Mucosa and Method for the Production Thereof |
| US20150250717A1 (en) * | 2014-03-06 | 2015-09-10 | Taris Biomedical Llc | Drug delivery systems and methods for treatment of bladder cancer with gemcitabine |
| JP7067229B2 (ja) | 2018-04-17 | 2022-05-16 | 信越化学工業株式会社 | 反応性ケイ素含有基を有するポリマーおよびその製造方法 |
-
2020
- 2020-10-02 JP JP2021551622A patent/JP7660066B2/ja active Active
- 2020-10-02 US US17/762,279 patent/US20220370630A1/en active Pending
- 2020-10-02 WO PCT/JP2020/037640 patent/WO2021066175A1/ja not_active Ceased
- 2020-10-02 EP EP20871804.9A patent/EP4039279A4/en active Pending
-
2025
- 2025-03-31 JP JP2025059920A patent/JP2025094276A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015005458A1 (ja) | 2013-07-10 | 2015-01-15 | 生化学工業株式会社 | グリコサミノグリカン誘導体及びその製造方法 |
| JP2017036455A (ja) | 2015-01-09 | 2017-02-16 | 生化学工業株式会社 | コンドロイチン硫酸誘導体及び膀胱疾患処置剤 |
Non-Patent Citations (2)
| Title |
|---|
| ONISHI, H. et al.,Conjugate between Chondroitin Sulfate and Prednisolone with Glycine Linker: Preparation and in Vitro Conversion Analysis,Chem. Pharm. Bull.,2013年,Vol.61, No.9,pp.902-912 |
| 宮本葵ほか,液体クロマトグラフィー/質量分析法を用いる環境水中副腎皮質ステロイド類分析法の開発,BUNSEKI KAGAKU,2010年,Vol.59, No.4,pp.301-309 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4039279A1 (en) | 2022-08-10 |
| JP2025094276A (ja) | 2025-06-24 |
| EP4039279A4 (en) | 2023-11-01 |
| JPWO2021066175A1 (cg-RX-API-DMAC7.html) | 2021-04-08 |
| US20220370630A1 (en) | 2022-11-24 |
| WO2021066175A1 (ja) | 2021-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108350022B (zh) | 聚乙二醇缀合的糖皮质激素前体药物及其组合物和方法 | |
| JP6144383B2 (ja) | 薬物送達系の構成成分の一時的コンジュゲーションのための調整可能な生分解性リンカー分子、及びそれを用いて調製される薬物送達系 | |
| JP2025094276A (ja) | 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム、医薬組成物、及び膀胱疾患処置剤 | |
| HU216636B (hu) | Eljárás epesavszármazékok előállítására | |
| CA2625532C (en) | Agent for applying to mucosa containing a hydrophobic group binding type glycosaminoglycan | |
| JP2019059951A (ja) | グリコサミノグリカン誘導体及びその製造方法 | |
| US10953037B2 (en) | Chondroitin sulfate derivative and agent for treating bladder diseases | |
| EP3020417A1 (en) | Pharmaceutical composition for respiratory administration | |
| WO2005085294A1 (ja) | ヒアルロン酸−メトトレキサート結合体 | |
| CN114430756B (zh) | 担载短链脂肪酸酯的亲水-疏水性共聚物 | |
| JP2023513086A (ja) | 炎症性疾患を処置するための胆汁酸-gcpii阻害剤コンジュゲート | |
| HK40039515A (en) | Chondroitin sulfate derivative and agent for treating bladder diseases | |
| KR102462782B1 (ko) | 환원반응성 일산화질소 공여 화합물 및 전달체 시스템 | |
| JP5201546B2 (ja) | N‐アセチルシステイン抱合型胆汁酸、それを含有する医薬組成物及びその製造方法 | |
| CN1462752A (zh) | 化疗药物-偕二膦酸偶联物及其合成方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20220614 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230922 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230922 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240926 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250212 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250306 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250331 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7660066 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |